Myrbetriq be generic?

When will Myrbetriq go generic?

Myrbetriq (duloxetine), marketed by Astellas Pharma, is a medication used to treat overactive bladder (OAB) and benign prostatic hyperplasia (BPH) symptoms in men. To find out when a generic version of Myrbetriq might become available, let's look at the patent information [1] provided on DrugPatentWatch.com.

How long are patents for Myrbetriq?

The FDA approved Myrbetriq in 2012, and Astellas Pharma held an exclusive marketing license for the product until [2] 2029. The original patent for Myrbetriq expired on [3] 2029. However, additional patents extending the protection period might exist.

Additional patents and exclusives

Several additional patents and exclusives have been granted for Myrbetriq, which may delay the entry of generic versions onto the market. As of [4] DrugPatentWatch.com listed a few patent extensions, but no further information is available on how many or which specific patents will continue to safeguard the Myrbetriq exclusivity. The exact timing and availability of a generic alternative depend on resolving existing litigation or potential disputes over these extended patents.

Patent expiration impact

The patent expiration in 2029 [5] will allow generic manufacturers to create lower-cost alternatives to Myrbetriq. The U.S. Food and Drug Administration (FDA) may accept an abbreviated new drug approval (ANDA) application for a generic version once the original patent and any subsequent extensions expire. Manufacturers would need to submit a copy of the approved Myrbetriq product with the ANDA, demonstrating the bioequivalence between the generic and branded versions.

How will a generic Myrbetriq impact the market?

When a generic Myrbetriq becomes available, the market for bladder medications like Myrbetriq and its competitors (e.g., Tamsulosin from Abbvie) could experience a decline in prices, increased accessibility for patients, and new market opportunities for generic manufacturers. The market is constantly evolving as more competitors enter, but we'll see what the future of the market holds.

Sources

1. (https://www.drugpatentwatch.com/patent/US-20120211573A1)
2. https://www.drugpatentwatch.com/patent/US-20230014342A1
3. https://www.drugpatentwatch.com/patent/US-20230014342A1
4. (https://www.drugpatentwatch.com/patent/US-20230014342A1)
5. https://www.drugpatentwatch.com/patent/US-20230014342A1